

Emerging Drugs and Targets for Parkinson's Disease

RSC Drug Discovery Series

Editor-in-Chief:

Professor David Thurston, *King's College, London, UK*

Series Editors:

Dr David Fox, *Vulpine Science and Learning, UK*

Professor Ana Martinez, *Medicinal Chemistry Institute-CSIC, Madrid, Spain*

Professor David Rotella, *Montclair State University, USA*

Advisor to the Board:

Professor Robin Ganellin, *University College London, UK*

Titles in the Series:

- | | |
|---|---|
| 1: Metabolism, Pharmacokinetics and Toxicity of Functional Groups | 20: Drug Design Strategies: Computational Techniques and Applications |
| 2: Emerging Drugs and Targets for Alzheimer's Disease; Volume 1 | 21: Designing Multi-Target Drugs |
| 3: Emerging Drugs and Targets for Alzheimer's Disease; Volume 2 | 22: Nanostructured Biomaterials for Overcoming Biological Barriers |
| 4: Accounts in Drug Discovery | 23: Physico-Chemical and Computational Approaches to Drug Discovery |
| 5: New Frontiers in Chemical Biology | 24: Biomarkers for Traumatic Brain Injury |
| 6: Animal Models for Neurodegenerative Disease | 25: Drug Discovery from Natural Products |
| 7: Neurodegeneration | 26: Anti-Inflammatory Drug Discovery |
| 8: G Protein-Coupled Receptors | 27: New Therapeutic Strategies for Type 2 Diabetes: Small Molecules |
| 9: Pharmaceutical Process Development | 28: Drug Discovery for Psychiatric Disorders |
| 10: Extracellular and Intracellular Signaling | 29: Organic Chemistry of Drug Degradation |
| 11: New Synthetic Technologies in Medicinal Chemistry | 30: Computational Approaches to Nuclear Receptors |
| 12: New Horizons in Predictive Toxicology | 31: Traditional Chinese Medicine |
| 13: Drug Design Strategies: Quantitative Approaches | 32: Successful Strategies for the Discovery of Antiviral Drugs |
| 14: Neglected Diseases and Drug Discovery | 33: Comprehensive Biomarker Discovery and Validation for Clinical Application |
| 15: Biomedical Imaging | 34: Emerging Drugs and Targets for Parkinson's Disease |
| 16: Pharmaceutical Salts and Cocrystals | |
| 17: Polyamine Drug Discovery | |
| 18: Proteinases as Drug Targets | |
| 19: Kinase Drug Discovery | |

How to obtain future titles on publication:

A standing order plan is available for this series. A standing order will bring delivery of each new volume immediately on publication.

For further information please contact:

Book Sales Department, Royal Society of Chemistry, Thomas Graham House, Science Park, Milton Road, Cambridge, CB4 0WF, UK

Telephone: +44 (0)1223 420066, Fax: +44 (0)1223 420247,

Email: booksales@rsc.org

Visit our website at www.rsc.org/books

Emerging Drugs and Targets for Parkinson's Disease

Edited by

Ana Martinez and Carmen Gil

Instituto de Química Médica-CSIC, Madrid, Spain

Email: amartinez@iqm.csic.es, cgil@iqm.csic.es

RSC Drug Discovery Series No. 34

ISBN: 978-1-84973-617-6
ISSN: 2041-3203

A catalogue record for this book is available from the British Library

© The Royal Society of Chemistry 2013

All rights reserved

Apart from fair dealing for the purposes of research for non-commercial purposes or for private study, criticism or review, as permitted under the Copyright, Designs and Patents Act 1988 and the Copyright and Related Rights Regulations 2003, this publication may not be reproduced, stored or transmitted, in any form or by any means, without the prior permission in writing of The Royal Society of Chemistry or the copyright owner, or in the case of reproduction in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK, or in accordance with the terms of the licences issued by the appropriate Reproduction Rights Organization outside the UK. Enquiries concerning reproduction outside the terms stated here should be sent to The Royal Society of Chemistry at the address printed on this page.

The RSC is not responsible for individual opinions expressed in this work.

Published by The Royal Society of Chemistry,
Thomas Graham House, Science Park, Milton Road,
Cambridge CB4 0WF, UK

Registered Charity Number 207890

For further information see our web site at www.rsc.org

Preface

“Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.”

Sir Winston Churchill

Despite the great goals achieved in our era, such as reaching the moon or finding the Higgs particle among others, human health remains fragile and our current therapeutic arsenal is completely insufficient to cure many severe diseases. Drug discovery today is fueled by the urgent need to find effective drugs for many unmet pathologies.

Parkinson's disease, the second most common neurodegenerative disorder, is one of the above mentioned pathologies. Following the death of dopamine-generating cells in the *substantia nigra*, it is characterized by progressive loss of muscle control, which leads to trembling of the limbs and head while at rest, stiffness, slowness, and impaired balance. As symptoms worsen, it may become difficult to walk, talk and complete simple tasks. The first descriptions of Parkinson's disease date back as far as 5000 BC. Around that time, an ancient Indian civilization called the disorder 'Kampavata' and treated it with the seeds of a plant containing therapeutic levels of what is today known as levodopa. The disease is named after the British doctor James Parkinson, who published its first detailed description in *An Essay on the Shaking Palsy* in 1817.

Although more than 5 million people worldwide are affected by Parkinson's disease, currently there is no treatment to cure this mid-brain neurodegenerative pathology. Several therapies are available to delay the onset of motor symptoms, and to ameliorate motor symptoms, thereby extending the patient's quality of life.

Recent research advances in molecular biology and technology have provided multiple credible hypotheses around which therapeutic agents can be developed. This book collects some of the most outstanding examples of new

drugs currently under pharmaceutical development or new targets in the validation process that will reach the Parkinson's drugs market over the next few years as disease-modifying drugs. These new drugs will be able to provide effective treatment for motor and non-motor symptoms.

We wish to thank all of the contributors to the chapters in this book, firstly for their faith in the project, and we would like also to express our great appreciation to all of them for delivering clear, comprehensive reviews that will inform and enlighten readers on the state-of-the-art in their respective fields of research. We would also like to thank our families and students for their patience when we were immersed in editing, and the staff at the RSC, especially Gwen Jones and Cara Sutton, for their support in bringing the book to completion. It is very much hoped that this book will provide a useful resource to scientists, both in industry and academia, who are looking to find a solution for the many patients worldwide waiting for effective drugs.

Ana Martinez

Carmen Gil

Instituto de Química Médica-CSIC

Madrid, Spain

Contents

Introduction

Chapter 1 Parkinson's Disease: Symptoms, Unmet Needs and New Therapeutic Targets	3
<i>Mónica M. Kurtis and Pablo Martinez-Martín</i>	
1.1 Introduction	3
1.2 Motor Signs and Symptoms	4
1.2.1 Bradykinesia	4
1.2.2 Rigidity	7
1.2.3 Rest Tremor	7
1.2.4 Gait Disturbances	7
1.2.5 Motor Fluctuations and Dyskinesias	8
1.2.6 Dystonia	8
1.3 Non-Motor Symptoms	9
1.3.1 Neuropsychiatric Symptoms	9
1.3.2 Sleep Disturbances	12
1.3.3 Dysautonomia	13
1.3.4 Other Symptoms	15
1.4 Clinical Parkinson's Disease Subtypes	16
1.4.1 Empirically Driven Subtypes	17
1.4.2 Data-Driven Subtypes	17
1.5 Current Diagnosis	18
1.6 Current Treatment	18
1.7 Unmet Needs and New Therapeutic Targets	19
1.7.1 Symptoms Beyond the Dopamine Scope	19
1.7.2 Biomarkers	20
1.7.3 The Cure: Cause-Directed Therapy	21
1.7.4 Neuroprotection	21
References	21

RSC Drug Discovery Series No. 34
Emerging Drugs and Targets for Parkinson's Disease
Edited by Ana Martinez and Carmen Gil
© The Royal Society of Chemistry 2013
Published by the Royal Society of Chemistry, www.rsc.org

Chapter 2	Molecular Pathogenesis and Pathophysiology of Parkinson's Disease: New Targets for New Therapies	26
	<i>José G. Castaño, Carmen González, José A. Obeso and Manuel Rodríguez</i>	
2.1	Introduction	26
2.2	Molecular Pathogenesis of Parkinson's Disease	27
2.2.1	Genetic Channels	29
2.2.2	Metabolic Disturbance Channel Toxins	31
2.2.3	Inflammatory and Immunity Channels	32
2.2.4	Reactive Oxygen and Nitrogen Species Channels	32
2.2.5	Channels of Mitochondrial DNA Mutations	32
2.2.6	Channels of Somatic Nuclear Mutations	33
2.2.7	Channels of Cell Division Activation	34
2.2.8	Connecting Channels to Define the Pathogenesis of Parkinson's Disease	34
2.2.9	Transcriptional Re-Programming and Epigenetic Control	36
2.3	The Pathophysiology of Parkinson's Disease	38
2.3.1	Dopaminergic Neurons are Complex	38
2.3.2	Dopamine Cells are Not the Only ones Involved in PD	40
2.3.3	New Models of the Basal Ganglia are Necessary to Understand Parkinson's Disease	41
2.3.4	New Structural Data for the Basal Ganglia Model	42
2.3.5	Functional Data to be Included in the Basal Ganglia Model	45
2.4	Targets for New Parkinson's Disease Therapies	45
	Acknowledgements	47
	References	48

L-DOPA and Dopaminergic Agents

Chapter 3	Dopaminergic Treatments for Parkinson's Disease: Light and Shadows	61
	<i>Nicola Simola</i>	
3.1	Introduction	61
3.2	Overview of the Drugs used in Dopamine-Replacement Therapy	63
3.2.1	L-DOPA	63
3.2.2	Adjuncts to L-DOPA: COMT and MAO Inhibitors	63
3.2.3	Dopaminergic Agonists	63

<i>Contents</i>	ix
3.3 Effect of Dopamine-Replacement Therapy on the Motor Features of Parkinson's Disease	68
3.3.1 Motor Impairment	68
3.3.2 Motor Complications	69
3.4 Effect of Dopamine-Replacement Therapy on the Non-Motor Features of Parkinson's Disease	71
3.4.1 Non-Motor Symptoms	71
3.4.2 Addictive-Like Behavior Associated with Dopamine-Replacement Therapy	72
3.5 Effect of Dopamine-Replacement Therapy on Disease Progression	73
3.6 Future Directions in Dopamine-Replacement Therapy	76
3.6.1 Continuous Drug Delivery	76
3.6.2 Development of New Drugs	76
3.7 Final Remarks	77
Acknowledgements	77
References	77
Chapter 4 Catechol-O-Methyl-Transferase Inhibitors: Present Problems and Relevance of the New Ones	83
<i>P. Nuno Palma, László E. Kiss and Patrício Soares-da-Silva</i>	
4.1 Introduction	83
4.2 The Role of COMT Inhibitors in the Symptomatic Treatment of Parkinson's Disease	84
4.3 Pyrogallol and Catechol Derivatives as COMT Inhibitors	85
4.4 Nitrocatechol COMT Inhibitors	88
4.5 Non-Clinical Pharmacology of COMT Inhibitors	92
4.6 Metabolic Profile of COMT Inhibitors	93
4.7 Human Pharmacology	95
4.8 New Insights into the Mechanism of COMT Inhibition	100
4.8.1 <i>In Vitro</i> Potency	100
4.8.2 <i>In Vivo</i> Duration of Action	103
4.9 Final Remarks	105
Acknowledgements	106
References	106
Chapter 5 Pharmacologic Management of Dopaminergic-Induced Dyskinesias in Parkinson's Disease	110
<i>Mildred D. Gottwald and Michael J. Aminoff</i>	
5.1 Introduction	110
5.2 Why Do Dyskinesias Occur?	111

5.3	Scales Used for Assessing Dyskinesias	111
5.4	Medical Therapies	112
5.4.1	Delaying the Onset of Dyskinesias with Dopamine Agonists	112
5.4.2	Therapeutic Strategies for Existing Dyskinesias	114
5.4.3	Parenteral Therapies	117
5.4.4	New Compounds in Development	119
5.5	Conclusion	122
	References	122
Chapter 6	D₃ Receptor Agonists and Antagonists as Anti-Parkinsonian Therapeutic Agents	126
	<i>Mark Johnson and Aloke Dutta</i>	
6.1	Introduction: The D ₃ Receptor	126
6.1.1	D ₃ Localization and Distribution in the Brain	127
6.2	D ₃ Receptor-Selective Ligands	128
6.2.1	D ₃ Receptor-Selective Agonists	129
6.2.2	D ₃ Receptor-Selective Antagonists	131
6.3	Role of D ₃ Receptors in Levodopa-Induced Dyskinesias	134
6.3.1	D ₃ Receptor Modulation in the Treatment of Levodopa-Induced Dyskinesias	136
6.4	Neuroprotective Action of D ₃ Receptor-Preferring Agonists	138
6.4.1	D ₃ Receptor-Independent Neuroprotection	139
6.5	Conclusion	142
	Acknowledgements	142
	References	142
Chapter 7	Protein Phosphatases in Parkinson's Disease	149
	<i>Petr Heneberg</i>	
7.1	Introduction	149
7.2	Protein Tyrosine Phosphatases	149
7.2.1	Receptor Protein Tyrosine Phosphatase β/ζ	150
7.2.2	Protein Tyrosine Phosphatase PTP-PEST	151
7.2.3	Striatum-Enriched Protein Tyrosine Phosphatase	151
7.2.4	Src Homology 2 Domain-Containing Phosphatase 2	153

<i>Contents</i>		xi
7.2.5	Phosphatase and Tensin Homolog Deleted on Chromosome 10	154
7.2.6	Dual-Specificity Protein Phosphatase 1	156
7.3	Protein Serine/Threonine Phosphatases	157
7.3.1	Protein Phosphatase 1	158
7.3.2	Protein Phosphatase 2A	160
7.3.3	Protein Phosphatase 3	163
7.3.4	PH Domain Leucine-Rich Repeat Protein Phosphatase 1	163
7.4	Future Views	164
	Acknowledgments	164
	References	164

The α -Synuclein Hypothesis

Chapter 8	Synuclein and Parkinson's Disease: An Update	175
	<i>Kurt A. Jellinger</i>	
8.1	Introduction: α -Synuclein and Disease	175
8.2	The Synuclein Family	176
8.3	The Biochemistry of α -Synuclein	176
8.3.1	Structure	176
8.3.2	Localization and Regulation	177
8.3.3	Physiological Functions	179
8.3.4	Genetics	180
8.4	α -Synuclein and Neurodegeneration	183
8.4.1	α -Synuclein Neurotoxicity and the Oligomer Toxicity Hypothesis	184
8.4.2	Mitochondrial Involvement in Parkinson's Disease	187
8.4.3	Lysosomal Dysfunction and Autophagy	188
8.4.4	Oxidative and Nitrate Injuries	189
8.4.5	α -Synuclein and Neuroinflammation	189
8.5	α -Synuclein Interaction with Other Proteins	190
8.6	α -Synuclein Spread and Disease Propagation	191
8.7	Neuropathology of Lewy Body Disorders	193
8.7.1	Sporadic Parkinson's Disease	193
8.7.2	Dementia with Lewy Bodies and Parkinson's Disease	196
8.8	Animal Models of Parkinson's Disease	197
8.9	α -Synuclein as a Biomarker for Synucleinopathies	197
8.10	Conclusions and Outlook for the Future	198
	References	200

Neuroprotective Therapies

Chapter 9	New Approaches to Neuroprotection in Parkinson's Disease <i>María Angeles Mena, Juan Perucho, José Luis López-Sendón and Justo García de Yébenes</i>	219
9.1	Introduction	219
9.2	Pathogenic Mechanisms in Parkinson's Disease due to Genetic Defects	221
9.2.1	α -Synuclein	221
9.2.2	PARKIN	223
9.2.3	Other Genes Involved in Hereditary Parkinsonism	224
9.3	Temporal Profile of Clinical Features and Pathological Changes Observed in Parkinson's Disease	225
9.3.1	The Temporal Spectrum on Clinical Findings	225
9.3.2	The Temporal Pattern of Pathological Changes	228
9.4	Neuroprotective Therapies: Towards Neuroprotection Based on Pathogenesis in Parkinson's Disease	229
	Acknowledgements	232
	References	232
 Chapter 10	 Glutamate Receptor Modulators as Emergent Therapeutic Agents in the Treatment of Parkinson's Disease <i>Sylvain Célanire, Benjamin Perry, Robert Lutjens, Sonia Poli and Ian J. Reynolds</i>	 237
10.1	Introduction	237
10.1.1	Glutamate Receptors: Nomenclature and Links with Parkinson's Disease	238
10.1.2	Allosteric Modulators <i>versus</i> Orthosteric Ligands	240
10.1.3	Animal Models of Parkinson's Disease	240
10.2	Recent Progress of Ionotropic Glutamate Receptor Modulators in Parkinson's Disease	241
10.2.1	NMDA Receptor Blockers	241
10.2.2	AMPA Receptor Modulators	244
10.3	Recent Progress of Metabotropic Glutamate Receptor Modulators in Parkinson's Disease	246
10.3.1	Group I mGluRs: Focus on mGluR5 Negative Allosteric Modulators	246
10.3.2	Group II mGluR Modulators	248
10.3.3	Group III mGluRs: Focus on mGluR4 and mGluR8 Activators	250

<i>Contents</i>	xiii
10.4 Clinical Development of Novel Glutamate-Based Therapeutics in Parkinson's Disease	253
10.4.1 NMDA Receptor Blockers	253
10.4.2 AMPA Receptor Modulators	254
10.4.3 mGluR5 Receptor Negative Allosteric Modulators	254
10.5 Conclusion and Perspectives	255
Acknowledgements	256
References	256
Chapter 11 LRRK2 Kinase Inhibitors as New Drugs for Parkinson's Disease?	266
<i>Sandra Schulz, Stefan Göring, Boris Schmidt and Carsten Hopf</i>	
11.1 Introduction	266
11.2 Insight into LRRK2 Inhibitor SARs from Structural Biology Studies and Molecular Modeling	267
11.3 Medicinal Chemistry for the Design of Potent and Selective LRRK2 Inhibitors	269
11.3.1 Non-Selective LRRK2 Inhibitors	269
11.3.2 Potent and Selective LRRK2 Inhibitors	273
11.3.3 Examples from Recently Published Patent Applications	277
11.4 The Role of LRRK2 Outside the Brain and Implications for Potential Mechanism-Based Toxicity of LRRK2 Inhibitors as Drugs	277
11.5 Invertebrate and Vertebrate Animal Models for Pharmacological Evaluation of LRRK2 Inhibitors	282
11.6 Pharmacokinetics and Pharmacodynamics of LRRK2 Inhibitors: The Current State-of-the-Art	284
11.7 Will LRRK2 Kinase Inhibitors be Developed into Drugs (for the Treatment of Parkinson's Disease)?	286
11.7.1 Patient Stratification	287
11.7.2 Mechanism-Based Toxicity	288
11.7.3 Utility in Other Therapy Areas Besides Parkinson's Disease	288
References	289
Chapter 12 Phosphodiesterase Inhibitors as a New Therapeutic Approach for the Treatment of Parkinson's Disease	294
<i>Ana Martinez and Carmen Gil</i>	
12.1 Introduction	294
12.2 Dopamine and Cyclic Adenosine Monophosphate	295

12.3	Phosphodiesterases and their Role in Dopamine Signaling	296
12.4	Phosphodiesterases as Drug Targets Beyond Dopamine	298
12.5	Phosphodiesterase Inhibitors as New Drugs for Parkinson's Disease	298
12.5.1	PDE1 Inhibitors	300
12.5.2	PDE4 Inhibitors	300
12.5.3	PDE7 Inhibitors	301
12.5.4	PDE10 Inhibitors	302
12.6	Conclusions	303
	Acknowledgements	303
	References	303

Chapter 13 5-HT_{1A} Receptors as a Therapeutic Target for Parkinson's Disease **308**

Saki Shimizu and Yukihiro Ohno

13.1	Introduction	308
13.2	5-HT _{1A} Receptors	310
13.3	Role of 5-HT _{1A} Receptors in the Treatment of Parkinson's Disease	312
13.3.1	Treatment of Parkinsonian Symptoms	312
13.3.2	Treatment of L-DOPA-Induced Dyskinesia	314
13.3.3	Treatment of Non-Motor Symptoms in Parkinson's Disease	316
13.4	5-HT _{1A} Receptor Ligands	320
13.5	Conclusion	320
	References	322

Chapter 14 Tryptophan Metabolism in Parkinson's Disease: Future Therapeutic Possibilities **327**

Zsófia Majláth and László Vécsei

14.1	Introduction	327
14.2	Tryptophan Metabolism	328
14.2.1	Serotonin Pathway	328
14.2.2	Kynurenine Pathway	328
14.3	Pathogenesis of Parkinson's Disease	330
14.3.1	Some of the Main Aspects of the Pathogenesis of Parkinson's Disease	330
14.3.2	Altered Tryptophan Metabolism in Parkinson's Disease	331

<i>Contents</i>	xv
14.4 Future Therapeutic Possibilities	333
14.5 Conclusions	334
Acknowledgements	335
References	335
Chapter 15 Role of P2X7 Receptor Signaling in the Treatment of Parkinson's Disease and Other Neurodegenerative Disorders	341
<i>Takato Takenouchi, Kazunari Sekiyama, Masayo Fujita, Shuei Sugama, Yoshifumi Iwamaru, Hiroshi Kitani and Makoto Hashimoto</i>	
15.1 Introduction	341
15.2 Role of Neuroinflammation in the Progression of Parkinson's Disease	342
15.2.1 Neuroinflammation in Parkinson's Disease Brains and Animal Models of Parkinson's Disease	342
15.2.2 Role of IL-1 β in Neuroinflammation in the Progression of Parkinson's Disease	343
15.3 Expression in the Central Nervous System and Drugs for the Modulation of P2X7R	345
15.3.1 P2X7R Expression in the Central Nervous System	345
15.3.2 The Dual Neuroprotective and Neurotoxic roles of P2X7R	346
15.3.3 Modulators of P2X7R Function	347
15.4 Altered Expression and Function of P2X7R in Parkinson's and Other Neurodegenerative Conditions	349
15.5 Effects of P2X7R Modulators or Deficiency in Animal Models of Parkinson's and Other Neurodegenerative Diseases	351
15.5.1 Effects of P2X7R Antagonists or Deficiency	351
15.5.2 Possible Effects of Other P2X7R Modulators	353
15.6 Conclusion and Perspective	354
Acknowledgements	355
References	355

Neuroregenerative Strategies

Chapter 16 Carotid Body Transplants as a Therapy for Parkinson's Disease	363
<i>Javier Villadiego, Ana Belén Muñoz-Manchado, Simón Mendez-Ferrer, Juan José Toledo-Aral and José López-Barneo</i>	
16.1 Cell Therapy in Parkinson's Disease	363
16.2 Anatomical and Physiological Features of the Carotid Body	364
16.3 Carotid Body Cell Therapy for Parkinson's Disease	366
16.3.1 Initial Preclinical Studies: The Carotid Body as a Source of Dopamine Cells	366
16.3.2 Recent Preclinical Studies: The Carotid Body as a Biological Pump Releasing Dopaminotrophic Factors	367
16.4 Clinical Studies of Carotid Body Autotransplantation on Parkinson's Disease Patients	371
16.5 Conclusions and Perspectives	372
Acknowledgements	373
References	373
 Chapter 17 Stem-Cell-Based Cell-Replacement Therapy in Parkinson's Disease	 376
<i>Jan Tønnesen and Merab Kokaia</i>	
17.1 Parkinson's Disease and Cell-Replacement Therapy	376
17.2 Proof-of-Principle: Fetal-Cell-Replacement Therapy	377
17.3 Candidate Stem Cells for Parkinson's Disease Cell-Replacement Therapy	378
17.3.1 Fetal Neural Stem Cells	378
17.3.2 Embryonic Stem Cells	379
17.3.3 Induced Pluripotent Stem Cells	379
17.3.4 Directly Induced Neurons	382
17.4 Stem Cell Integration in a Host Tissue	382
17.5 Genetically Enhanced Stem Cells	384
17.6 Concluding Remarks and Future Perspectives	384
References	385
 Subject Index	 390

Introduction

CHAPTER 1

Parkinson's Disease: Symptoms, Unmet Needs and New Therapeutic Targets

MÓNICA M. KURTIS*^a AND
PABLO MARTINEZ-MARTÍN^{b,c}

^a Movement Disorders Unit, Department of Neurology, Hospital Ruber Internacional, Madrid, Spain; ^b Area of Applied Epidemiology, National Centre of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain; ^c Alzheimer Disease Research Unit, CIEN Foundation, Carlos III Institute of Health, Alzheimer Center Reina Sofia Foundation, Madrid, Spain

*Email: mkurtis@ruberinternacional.es

1.1 Introduction

Since James Parkinson wrote the first systematic clinical description of six patients in 1817 in his essay titled “Paralysis Agitans”,¹ Parkinson’s disease (PD) has been considered a motor disorder, consisting of tremor, rigidity and gait difficulties. A few decades later, Jean Martin Charcot characterized the feature of bradykinesia and added other observations not pertaining to the motor domain, consisting of arthropathy, dysautonomia, and pain.² In the mid 1950s, pathological changes in the PD mid-brain described as “neuronal degeneration of the *substantia nigra*” were defined by Greenfield and Bosanquet.³ The delineation of the nigrostriatal pathway in the 1960s and discovery by Arvid Carlsson and colleagues of the direct correlation between

striatal dopamine loss and clinical Parkinsonian manifestations were a major breakthrough in the neurosciences and provided the opportunity for the development of effective therapies.⁴ In 1967 George Cotzias and others demonstrated the benefits of oral levodopa in patients, paving the way for substitutive dopaminergic treatments.^{5,6}

1.2 Motor Signs and Symptoms

Based on these early findings, the classic features that define the Parkinsonian syndrome are: bradykinesia, rigidity, tremor at rest, and gait disturbances (flexed posture, freezing, and loss of postural reflexes). At least two of these signs should be present before the diagnosis of Parkinsonism is put forth.⁷ The etiology is widely variable, therefore multiple primary and secondary causes must be considered when evaluating a patient, considering that PD is the most prevalent of the primary causes. In the following section, the well-established PD motor symptoms are enumerated and defined (Table 1.1).

1.2.1 Bradykinesia

The terms akinesia, literally means absence; bradykinesia, meaning slowness; and hypokinesia, meaning decreased amplitude; are all used, often interchangeably, to describe the most prominent phenomena of Parkinsonism. Patients show poverty of automatic movements (*i.e.*, blinking, arm swing) and also present reduced speed when initiating and executing single and repetitive movements with progressive loss of amplitude. Characteristically, there is greater difficulty in moving with self-initiated cues than with externally triggered movements and this abnormal activation and slowness affects most body parts.

Pathophysiology of bradykinesia can generally be explained by the classic model of the basal ganglia–thalamocortical circuitry postulated in the 1980s. In the absence of dopamine, the main output nucleus of the basal

Table 1.1 The motor symptom and sign complex of PD.

<i>Axial symptoms</i>	<i>Limb symptoms</i>
Hypomimia	Micrographia
Blepharospasm	Loss of dexterity
Hypophonia	Asymmetric arm swing
Dysarthria	Slow gait
Dysphagia	Rest tremor of the hand or foot
Sialorrhea	Foot dystonia
Chin, lip and tongue tremor	
Vertical eye movement restriction and convergence insufficiency	
Freezing of gait	
Flexed posture	
Loss of postural reflexes	
Camptocormia	

ganglia, the *globus pallidus interna* (GPi) is abnormally active, thus inhibiting the ventroanterior and ventrolateral motor thalamus, and subsequently the primary motor cortex, resulting in slowness. Current findings add complexity to the model, attempting to explain the other features of akinesia. It is hypothesized that the main disturbances in PD are the non-generation of phasic neurons, and the time-locked inhibition of GPi neurons which cannot facilitate recruitment of cortical motor neurons that are appropriately adjusted to produce voluntary movement. The primary motor cortex is also altered and there is a functional uncoupling with premotor areas that is not well understood. The loss of automatic movements in PD is probably related to alterations of basal ganglia projections to the brainstem central pattern generators, with excessive inhibition being the net result.⁸

1.2.1.1 *Hypomimia*

Bradykinesia affecting the facial muscles results in decreased expression, sometimes called 'poker' face, alluding to card players that do not show any emotion during their game, and can be an initial sign of the disease. This sign can also be seen in depressed patients and the differential diagnosis must be kept in mind. With disease progression, the lips can remain open most of the time and blink rate becomes severely decreased, leading to ocular problems such as dry eye.

1.2.1.2 *Hypophonia*

Hypophonia, meaning soft voice, is an axial sign that can also be a first complaint and is generally noted by the patient's family and friends. The person with PD is usually unaware that he/she is speaking softly and tends to blame others for being 'hard of hearing'. Some patients complain that their tone of voice has changed and become monotonous (termed "aprosody").

1.2.1.3 *Dysarthria*

Difficulty in articulating language is a reflection of bradykinesia of the tongue, oral cavity and larynx musculature. Some patients may talk too fast, presenting tachyphemia, others may stutter, due to freezing of speech episodes, and in advanced stages of the disease, patients may develop progressively severe mumbling that can make language unintelligible.

1.2.1.4 *Dysphagia*

Difficulty swallowing secondary to neurological disease generally affects liquids more than solids. Patients complain of coughing during their meals due to minor choking episodes and with disease progression, dysphagia may be severe and lead to aspiration, causing pulmonary infections such as pneumonia. In order to avoid this, patients must be instructed to maintain proper posture

when swallowing and avoid food textures, liquids and volumes they have difficulty managing. Ultimately, gastrostomy may be considered although the danger of saliva aspiration is not avoided.

1.2.1.5 *Sialorrhea*

Excessive salivation is probably secondary to decreased spontaneous swallowing although in some patients, saliva characteristics can differ from normal (becoming denser), and thus hypersalivation may also be considered a non-motor dysautonomic problem.

1.2.1.6 *Eye Movement Abnormalities*

In the past two decades, neuro-ophthalmologic symptoms in PD have been objectively measured and thus defined. Horizontal and vertical pursuit can show bradykinesia and decreased amplitude even in the early stages of the disease⁹ and as in other body parts, slowness becomes increasingly marked with repetition.¹⁰ It is not infrequent to find restriction of vertical eye movements. The saccade system is also altered, showing characteristically slow and hypometric saccades, and occasionally prolonged latencies.^{11,12} Patients often complain of blurred or double vision, secondary to convergence insufficiency as Biousse *et al.* found in an early untreated PD cohort.¹³ This study also showed that, when compared to controls, PD patients declared more local ocular symptoms (irritation, pain, conjunctival redness), eyelid problems (blepharospasm and decreased blinking) and dry eye.¹³ Dry eye is probably multi-factorial, secondary to motor disturbances (decreased blinking), and dysautonomic changes of the lacrimal glands.¹⁴

1.2.1.7 *Micrographia*

Small handwriting can often be the first symptom noted when PD affects the dominant side of the body. Patients describe that their writing starts out normally but becomes increasingly smaller as they keep writing. Their handwriting can become illegible and their signature can change to the point of misunderstandings with banks and official documents.

1.2.1.8 *Slow Gait*

Some patients' initial complaint is that they walk more slowly. They describe walking as tremendously effortful, since their legs feel heavy, as if they had weights pulling them down. Often a person close to them will note that they have decreased arm swing, usually asymmetric. Recent studies show that there are marked alterations in the rhythmicity and timing of gait, even in the early stages of the disease when speed can be intact.¹⁵

1.2.2 Rigidity

Rigidity is defined as increased muscle tone at rest that can be palpated, reduced distension when the limb is passively moved, increased resistance when the limb is stretched, and facilitation of the shortening reaction.⁸ Resistance is more noticeable when the limb is passively moved slowly, can manifest as cog-wheeling since the limb gives way in a stepwise fashion, and is increased with voluntary movement of other body parts (Froment's maneuver). Flexor muscles are generally affected earlier than the extensors. Rigidity is not explained by the classic model of the Parkinsonian state, where overactivity of the basal ganglia's main output nucleus (GPi) leads to cortical inhibition. Projections to the brainstem and spinal mechanisms probably play an important role as experimental findings suggest that spinal cord motorneurons present a shift towards increased activity in response to peripheral stimulation.⁸

1.2.3 Rest Tremor

Parkinsonian tremor usually involves distal parts of the extremities (called "pill rolling" when the thumb and index are involved) or the lips and chin, and characteristically occurs at rest. About two thirds of patients with PD show the typical rest tremor with a frequency measured by motor neurophysiological testing (electromyography and accelometry) of 4–5 Hz. Some rest tremors re-emerge after a short latency period of a few seconds, thus appearing during some actions such as posture holding. Kinetic and postural tremors can also be seen, but are generally not significant and do not interfere with the patient's activities. The pathophysiological mechanism behind PD tremor is unclear. To date there is no proven model that explains the link between dopamine deficiency and abnormal oscillatory activity in an extensive motor network that involves the basal ganglia, the cerebellum, the thalamus and the motor cortex.⁸

1.2.4 Gait Disturbances

1.2.4.1 Freezing of Gait

When initiating gait or turning, the feet literally become stuck to the ground, so the patient feels he/she cannot take a step. Some patients may present freezing in the initial stages of the disease, although it is rare in the first three years. The problems begin when they want to initiate gait (start hesitation), when turning, in tight spaces, or in doorways. With disease progression, patients develop destination freezing (*i.e.*, stopping a few steps from the chair where they want to sit) and freezing may interrupt gait at any time, even in open spaces. Characteristically patients with freezing do not have trouble with other complex motor programs such as climbing stairs or riding a bicycle. To date, the physiopathology of freezing is not well understood and the best treatment for freezing is based on physiotherapy since most patients benefit from external visual or auditory cues.

1.2.4.2 *Flexed Posture*

As the disease advances, patients tend to walk with flexion at the neck, elbows, hips and knees, with the forearms placed in front of the body. When extreme, this flexed posture can lead to pronounced kyphoscoliosis.

1.2.4.3 *Loss of Postural Reflexes*

Balance is tested in the office by a gentle pull backwards on the shoulders by the examiner. In the early stages of the disease, patients may have to take a few steps backwards (up to two is considered normal) in order to regain their balance. As the disease progresses, patients will not be able to recuperate due to loss of postural reflexes and falls become a major problem.

1.2.4.4 *Festination*

The patient with a festinating gait walks progressively faster and faster, taking shorter and shorter steps as he/she tries to catch up with his/her axial center of gravity. It is a result of stooped posture and altered postural reflexes.

1.2.4.5 *Falls*

One of the symptoms with highest morbidity in PD is falling, conditioned by multiple factors. Freezing is one of the primary etiologies of falls, as the body moves forward or to the side when turning, but the feet do not follow. Festinating gait can also cause the patient to fall forward as eventually the lower limbs cannot catch up with the forward tilting trunk. Loss of postural reflexes means that any small obstacle or nudge will throw the patient off balance, generally leading to a fall backwards. Cognitive impairment also plays a role in patients' falls, since loss of insight and risk appraisal can be affected.

1.2.5 **Motor Fluctuations and Dyskinesias**

With disease progression, treated patients may develop motor fluctuations, signifying they present what is termed an “off” state, in which their motor symptoms re-appear as medication benefits disappear, and an “on” state, when medications are effective and symptoms are well controlled. In addition to this, they may develop dyskinesias or involuntary movements that resemble chorea or dancing movements, generally appearing in the areas most affected by parkinsonism and probably secondary to dopamine receptor hypersensitivity.

1.2.6 **Dystonia**

Abnormal posturing due to sustained muscle contractions can be the first sign of the disease, or it can develop years later as a consequence of dopaminergic treatment, representing a similar phenomenon to dyskinesias. Axial dystonia

can affect the eyes, causing blepharospasm; the neck, usually producing ante-collis; or the trunk, resulting in camptocormia or stooped posture that increasingly worsens with walking, or Pisa syndrome, as patients lean the trunk to the side. Axial dystonia characteristically normalizes when standing against a wall or lying down. Secondary dystonia of the limbs can be associated with tremor (dystonic tremor), which tends to be faster and more erratic than the typical 4–5 Hz rest tremor, and when affecting the lower extremities can lead to abnormal gait.

1.3 Non-Motor Symptoms

At present, PD is still defined clinically by the presence of two or more of the cardinal motor symptoms described above. However, in the past decade, research has expanded to the prevalent non-motor symptom complex that affects patients during all stages of the disease, even in the premotor phase. Non-motor symptoms including sleep, mood, cognition, pain, and autonomic disorders have been identified as important PD manifestations, which often remain undeclared unless specifically sought.^{16,17} It is important to recognize and treat these symptoms since they are key determinants of patients' quality of life. Results of a recent study by our group showed that non-motor symptoms have, as a whole, a greater impact on health-related quality of life (HRQoL) than motor symptoms, and non-motor symptom progression contributes importantly to HRQoL decline in PD patients.¹⁸

The neurochemical and pathological substrates for most of the non-motor symptoms remain a puzzle. Key dopaminergic areas in the brain (the *substantia nigra pars compacta*, ventral tegmental area, and hypothalamus) project extensively to form four main circuits: the mesocortical, meso-limbic, nigro-striatal, and tuberoinfundibular pathways, which mediate several non-motor symptoms such as cognition, sleep, and pain. Other non-dopaminergic pathways depending on neurotransmitters such as serotonin, norepinephrine and acetylcholine also play a major role.¹⁹ Therefore, the non-motor symptoms that are classified and described in the next section may be modulated by dopaminergic therapy (Table 1.2) while others rarely respond.

1.3.1 Neuropsychiatric Symptoms

1.3.1.1 Depression

Depression is very frequent in PD patients, although prevalent cases range from 2.7 to 70%, depending on the study,²⁰ possibly due to differing methodologies. In practice, about 40% of patients²¹ show signs of depression which can be expressed as sadness, but often presents as irritability, hopelessness, pessimism or worry, more often than guilt or remorse, and contributes to insomnia and general slowness. Studies have suggested that depression is probably another premotor non-motor biomarker that can precede the development of clinical PD as it is currently defined.^{22–24} Serotonergic